Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Pfizer's stock has been trending on Zacks.com, with shares up 1.2% in the past month, lagging the S&P 500's 5.2% gain. While the current quarter's earnings are projected to decline 5% year-over-year to $0.57 per share, full-year earnings are estimated to decrease by 1.6%, with a slight increase of 0.8% expected for the next fiscal year; revenue forecasts show a similar slight decline. Despite these mixed results, Pfizer holds a Zacks Rank #2 (Buy) rating, suggesting potential near-term outperformance, and is considered undervalued relative to its peers based on Zacks' Value Style Score.

Analysis

Pfizer Inc. (PFE) has recently garnered significant investor attention, reflected in its status as a frequently searched stock on Zacks.com. Over the past month, PFE shares delivered a modest +1.2% return, underperforming the Zacks S&P 500 composite's +5.2% gain and contrasting sharply with the Zacks Large Cap Pharmaceuticals industry's -6.2% decline. Near-term earnings projections present a mixed picture: current quarter EPS is anticipated at $0.57, a -5% year-over-year decrease, with the consensus estimate revised down by -0.7% in the last 30 days. However, the current fiscal year's consensus EPS estimate of $3.06, though representing a -1.6% YoY change, has seen a +2.5% upward revision over the past month. Looking further, the next fiscal year's EPS is projected at $3.09, a +0.8% increase, with its estimate also revised upwards by +2% recently. These positive earnings estimate revisions contribute to Pfizer's Zacks Rank #2 (Buy). Revenue forecasts indicate a +2% YoY growth to $13.55 billion for the current quarter, but project slight declines of -0.6% to $63.25 billion for the current fiscal year and -0.5% to $62.92 billion for the next. In its last reported quarter, Pfizer's revenues of $13.72 billion marked a -7.8% YoY decrease and missed consensus by -0.88%, though EPS of $0.92 significantly beat estimates by +43.75% and improved from $0.82 a year ago. The company has a strong track record of beating EPS estimates in each of the last four quarters. From a valuation perspective, Pfizer holds a Zacks Value Style Score of A, suggesting it is currently trading at a discount relative to its peers.

Key Decisions for Investors

• Investors should note Pfizer's recent positive earnings estimate revisions for the current and next fiscal years, which underpin its Zacks Rank #2 (Buy), despite a projected near-term EPS decline and modest revenue outlook.
• Given the stock's 'A' grade for Value and its underperformance relative to the S&P 500 but outperformance against its industry, there may be an opportunity for value-oriented investors, though continued monitoring of revenue trends and earnings delivery is crucial.
• Consider the mixed signals: while last quarter's revenue missed expectations, the significant EPS beat and consistent history of surpassing EPS estimates, combined with an attractive valuation, could warrant a cautiously optimistic stance, pending further confirmation of a turnaround in revenue growth.